NCT05055258

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: KalVista Pharmaceuticals, Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

Conditions

• Angioedema, Hereditary, Types I and II

Interventions

Type	Name	Description
DRUG	KVD824	KVD824 300 mg Modified-Release Tablets
DRUG	Placebo to KVD824	Placebo to KVD824 300 mg Modified-Release Tablets

Timeline

• Start date: 2021-09-27
• Primary completion: 2022-10-27
• Completion: 2022-10-27
• First posted: 2021-09-24
• Last updated: 2023-10-10

Locations

33 sites across 13 countries: United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, New Zealand, North Macedonia, Puerto Rico, United Kingdom

Regulatory

• FDA-regulated drug study